Therefore, considering the idea that SFFAs activate macrophages and promote increased expression of IL-6 (Shi et al., 2006; Figure), our expectation is that IK may also be an important target for IL-6 modulation in AF pathogenesis in patients with metabolic disorders. The gene discussed is IL6; the disease is metabolic disease.